AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01256398
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01256398
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT, IV, or PO
Trial: NCT03216681
Drug: Hoat Huyet Nhat Nhat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally twice a day, 2 tablets each time, for 45 days.
Trial: NCT00061945
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00061945
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT, IV, and PO
Trial: NCT00061945
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00061945
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV and PO
Trial: NCT00086931
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral dose escalating, twice daily.
Trial: NCT00567346
Drug: Oralgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive drops of grass pollen immunotherapy sublingually
Trial: NCT01874730
Drug: Volulyte® (6% HES 130/0.4 in balanced solution)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the SOC Group: Intraoperative fluid management includes Volulyte® (6% HES 130/0.4 in balanced solution) as the only colloid solution to be used, the daily dosage of Volulyte® is restricted to 50 ml/kg.~For the ERS Group:~GDFT regimen will be utilized using Volulyte® (6% HES 130/0.4 in balanced solution) during surgery. The daily dosage of Volulyte® is restricted to 50 ml/kg.
Trial: NCT03406832
Drug: Heparinized saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion 2ml for single time
Trial: NCT04551755
Drug: Ivermectin and Doxycycline
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. Tab Ivermectin (6mg): 12mg first dose then one more dose of 12mgafter 12 hours~2. Cap. Doxycycline (100mg): 1+0+1 after meal for 10 days. To be taken with half glass of water and sit up for 20 minutes
Trial: NCT01322269
Drug: HQK-1001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HQK-1001 tablets, once daily for daily 26 weeks
Trial: NCT03481881
Drug: Standard of care drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study is collecting PK data on children prescribed the following drugs of interest per standard of care: dexmedetomidine, bosentan, furosemide, chlorothiazide, ethacrynic acid, bumetanide, hydromorphone, tacrolimus, ampicillin, gentamicin, caffeine, fentanyl, midazolam, foscarnet, hydroxychloroquine, and moxifloxacin.
Trial: NCT03021499
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo capsule
Trial: NCT00450242
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydrophilic petrolatum, dime-sized amount, applied nightly.
Trial: NCT00841204
Drug: sulindac
RxNorm normalized name: Sulindac
DrugBank: Sulindac (DB00605)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00411762
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00411762
Drug: PHY906
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00372762
Drug: Bumetanide
RxNorm normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Equivalent dose to pre-existing furosemide will be used
Trial: NCT00372762
Drug: bumetanide
RxNorm normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5mg to 2mg orally once or twice daily
Trial: NCT00870883
Drug: N-acetylcysteine and deferoxamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine bolus dose of 50mg/kg/4h, by a manutention of 100mg/kg/day during 2 days and deferoxamine single dose of 1g administered 15mg/kg/h.
Trial: NCT01227759
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo containing no active ingredient
Trial: NCT00820950
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream applied once or twice daily for 56 days
Trial: NCT04061798
Drug: ACT guided heparinization
RxNorm normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If the ACT is \<180 sec., an additional dose of heparin of 60 IU/kg is administered. If the ACT is 180-200 sec., 30 IU/kg.~If the ACT is \>200 sec., no extra heparin is given. 5 min. after every administration of heparin the ACT is measured. If the ACT is \>200 sec, the next ACT measurement is performed every 30 min., until the end of the procedure or until new heparin administration is required. After each new dose of heparin, an ACT measurement is performed after 5 min. and the above- described protocol of ACT measurements will be repeated. After re-establishing blood flow and removing all clamps, the ACT is measured.~If the ACT at closure is 200-250 sec., 2500 IU of protamine should be administered. If \>250 sec., 5000 IU protamine. If 180-200 sec., 1000 IU protamine. 5 min. after the administration of protamine, the ACT is measured. The ACT should preferably be below 180 sec. If the ACT is still more than 200 sec., protamine should be administered again.
Trial: NCT04061798
Drug: 5 000 IU of heparin
RxNorm normalized name: Heparine
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of 5 000 IU of heparin is given 3-5 min before clamping of the aorta. No ACT measurements are performed, except for one ACT measurement after re-establishing blood flow and removing all clamps. Only on clarified indications extra doses of heparin or protamine are permitted, at the discretion of the attending vascular surgeon. Indications could be clot formation intravascular or in a prosthesis, excessive bleeding or prolonged operation duration. Deviations from protocol should be clearly stated with reasoning in the operative report.~If the ACT at closure is between 200 and 250 s, 2500 IU protamine should be administered. If the ACT is higher than 250 s, 5000 IU protamine should be administered. If the ACT is between 180 and 200 s, 1000 IU protamine should be administered. Five minutes after the administration of protamine, the ACT is measured. The ACT should preferably be below 180 s. If the ACT is still more than 200 s, protamine should be administered again.
Trial: NCT00048893
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: First induction chemotherapy: 2700 mg/m\^2 per cycle (900 mg/m\^2 per day intravenous over 1 hour for 3 consecutive days, days 1-3).~Second induction: 600 mg/m\^2 per cycle (600 mg/m\^2 intravenous over 1 hour day 1.~Immune depleting chemotherapy: 2400 mg/m\^2 per cycle (600 mg/m\^2 per day intravenous over 1 hour for 4 consecutive days, days 1-4).
Trial: NCT00048893
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m\^2 per cycle (60 mg/m\^2 slow intravenous push day 1).
Trial: NCT03249831
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Orally daily
Trial: NCT04008030
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT04008030
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT04270552
Drug: Ismigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual tablets containing 7 mg of bacterial lysate from the following bacteria: Staphylococcus aureus, Haemophilus influenzae serotype B, Klebsiella pneumoniae, Klebsiella ozaenae, Neiserria catarrhalis, Streptococcus viridans, Streptococcus pyogenes, Streptococcus pneumoniae (6 strains: TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ24) - sublingual use 1 tablet per day over 10 days for 3 successive months.
Trial: NCT04270552
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched tablets without any active substance.
Trial: NCT00523718
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, 1 capsule PO bid, 12 weeks
Trial: NCT02414503
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04265456
Drug: Acetaminophen 1300mg
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen is a non-salicylate antipyretic and non-opioid analgesic agent.
Trial: NCT00686998
Drug: AZD2624
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Suspension
Trial: NCT00686998
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01494649
Drug: Test Toothpaste
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.454% stannous fluoride toothpaste
Trial: NCT03540043
Drug: Administration of Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botanical Drug Phase 2 clinical study
Trial: NCT03540043
Drug: Administration of PUR0110 (Thykamine) 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botanical Drug Phase 2 clinical study
Trial: NCT01748448
Drug: Placebo: Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02815917
Drug: [18F]FTP PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All PET/CT imaging sessions will include an injection of \[18F\]FTP. Pilot data will be collected to evaluate preliminary information on brain uptake of \[18F\]FTP in healthy volunteers and cocaine-dependent volunteers.
Trial: NCT03540043
Drug: Administration of PUR0110 (Thykamine) 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botanical Drug Phase 2 clinical study
Trial: NCT03540043
Drug: Administration of PUR0110 (Thykamine) 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botanical Drug Phase 2 clinical study
Trial: NCT01603238
Drug: [14C]-LC15-0444
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral administration of \[14C\]-LC15-0444 50 mg, containing 4.9 MBq \[14C\]. Subjects in the fasted state will receive the drug as a capsule, with 240 ml of water.
Trial: NCT01604109
Drug: 10 % w/v CPP-ACP paste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply once a day at school by school teacher, following fluoride toothbrushing after lunch
Trial: NCT03640559
Drug: Seroguard
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03640559
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00099320
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After a 2-week placebo lead-in period (twice daily, given subcutaneously) in addition to their current therapy regimen, subjects will administer placebo (in equivalent amounts to exenatide) for 16 weeks of therapy.
Trial: NCT03091400
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identically encapsulated placebo, with dose matched to experimental agent (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
Trial: NCT02561000
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01436162
Drug: Antidepressant + Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks
Trial: NCT01257828
Drug: Placebo medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg BID orally for 14 days prior to surgery and 28 days after the surgery
Trial: NCT04252521
Drug: dexketoprofen trometamol
RxNorm normalized name: Dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg dexketoprofen trometamol in 100 ml normal saline solution
Trial: NCT04252521
Drug: metoclopramide+dexketoprofen trometamol
RxNorm normalized name: dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg metoclopramide+50 mg dexketoprofen trometamol in 100 ml normal saline solution
Trial: NCT04959201
Drug: NMDAE plus AO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of an NMDA enhancer plus a drug with antioxidant property for the treatment of schizophrenia.
Trial: NCT04959201
Drug: NMDAE plus Placebo Cap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of an NMDA enhancer plus placebo as a comparator.
Trial: NCT00995540
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tid subcutaneous injection for 12 weeks
Trial: NCT03135548
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 weeks treatment
Trial: NCT02567539
Drug: Radiosensitive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiosensitive therapy with Temozolomide
Trial: NCT03997383
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (0.9% NaCl) matching volume of patisiran doses will be administered intravenously.
Trial: NCT02913261
Drug: Best Available Therapy (BAT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAT was based on the investigator's best judgment, taking into account the manufacturer's instructions, labeling, patient's medical condition, and institutional guidelines for any dose adjustment. The BAT in this study was identified by the investigator prior to patient randomization among the following treatments currently used in this setting: anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mesenchymal stromal cells (MSC), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, or infliximab. No other types or combinations of BAT were permitted.
Trial: NCT01191372
Drug: placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sterile saline for injection
Trial: NCT01191372
Drug: ARC19499
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-tissue factor pathway inhibitor (TFPI) aptamer
Trial: NCT00870220
Drug: Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH will be maintained at 0.05mg/kg/d, adjusted every 3 months. Estradiol 14mcg patch will be applied for 10 days/month for the first 6 months in Group 2. Estradiol 25mcg patch will be applied for 10 days/month for the second 6 months in Group 2, and for the first 6 months in Group 3. Estradiol 25mcg patch will be applied for 3 weeks per month for the second 6 months in Group 3.
Trial: NCT02994433
Drug: Placebo gas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gas given at 50% nitrogen \[inert\]/50% oxygen.
Trial: NCT04236141
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a total of 6 cycles (a cycle being 21 days) of Placebo (IV infusion) on Day 2 of Cycle 1 and Day 1 of Cycles 2-6.
Trial: NCT00060554
Drug: heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02616146
Drug: ENG-E2 125 μg/300 μg vaginal ring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 13 cycles of ENG-E2 125 μg/300 μg administered intravaginally, each cycle consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
Trial: NCT02616146
Drug: LNG-EE 150 μg/30 μg COC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 13 cycles of LNG-EE 150 μg/30 μg administered orally, each cycle consisting of one tablet per day for 21 days, followed a 7-day tablet-free interval.
Trial: NCT01340872
Drug: ST10-021
RxNorm normalized name: ZINC OXIDE 132 mg in 1 mL TOPICAL LOTION [ILIA SUPER SERUM SKIN TINT (ST10 PORTO FERRO)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg capsules to be taken orally twice a day for 12 weeks
Trial: NCT01340872
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching sugar pill to be taken orally twice a day for 12 weeks
Trial: NCT00257166
Drug: placebo oral capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength administered BID.
Trial: NCT02280395
Drug: RUT058-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior to closure of the abdomen at the end of the surgical repair, each subject will undergo lavage with approximately 900 mL of RUT058-60 administered as two 400 mL intra-abdominal (peritoneal) lavages and one 100 mL lavage above the fascia.
Trial: NCT02280395
Drug: Sterile saline for irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior to closure of the abdomen, each subject will undergo lavage with approximately 900 mL of sterile saline administered as two 400 mL intra-abdominal (peritoneal) lavages and one 100 mL lavage above the fascia.
Trial: NCT02088112
Drug: MEDI4736
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI4736 IV Q2W
Trial: NCT02418559
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo tablet orally once on Day 1 under fasted conditions.
Trial: NCT04600817
Drug: TJ107 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QW8
Trial: NCT03039621
Drug: Ergoferon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For oral use.
Trial: NCT03039621
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For oral use.
Trial: NCT01732094
Drug: hpHMG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hpHMG 300IU daily from day 7 following Corifollitropin alfa onwards
Trial: NCT01459029
Drug: D-serine
RxNorm normalized name: D-Serine
DrugBank: D-Serine (DB03929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant treatment with D-serine up to 6000 mg/day vs. placebo
Trial: NCT00140543
Drug: sirolimus versus mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02616445
Drug: UE2343
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * UE2343~* 10mg, 20, 35mg~* twice daily for 9 days
Trial: NCT02616445
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * 10mg, 20, 35mg~* twice daily for 9 days
Trial: NCT02616445
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Cross-over study~* single dose administered twice (on day 1 and day 8)~* study duration 17 days
Trial: NCT02616445
Drug: UE2343
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Cross-over study~* UE2343~* single dose administered twice (on day 1 and day 8)~* study duration 17 days
Trial: NCT02616445
Drug: UE2343
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * UE2343~* twice daily for 3 days~* single dose on day 4
Trial: NCT04621097
Drug: Medication
RxNorm normalized name: Acne Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: regular medications
Trial: NCT02015299
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet matching placebo/day for 26 weeks
Trial: NCT01727700
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04578548
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules administered orally
Trial: NCT03608072
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 sequential dose groups
Trial: NCT05420350
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pill matched with lamotrigine to be taken once or twice a day per study timeline Oral pill matched with bupropion to be taken twice a day
Trial: NCT01842633
Drug: Paracetamol and Caffeine
RxNorm normalized name: codeine and paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caplets containing 500 milligrams (mg) of paracetamol and 65 mg of caffeine
Trial: NCT01842633
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Caplets containing 200 mg of ibuprofen
Trial: NCT00095875
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00971165
Drug: Chlorthalidone plus amiloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Chlorthalidone plus amiloride up to 25 e 5 mg daily, once a day for 18 months
Trial: NCT01355484
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subject will receive placebo for the duration of the trial
Trial: NCT02677298
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection, 0.9% sodium chloride divided in five 0.1 mL i.m. injections into glabellar area
Trial: NCT00263796
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline, IV over 4 hours
Trial: NCT02616601
Drug: Generic Fluorouracil Cream
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical cream, generic formulation of the brand product.
Trial: NCT02616601
Drug: Carac® (Fluorouracil) Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cream, brand product.